Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery.
Matthieu GregoireJulia Brochard LiboisDenis WaastBenjamin GaboritMarc DautyGuillaume DeslandesEric DaillySophie TouchaisDavid BoutoilleNicolas GrégoireWilliam CouetPublished in: Antimicrobial agents and chemotherapy (2018)
An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC0-24) was 28.3 mg/liter · h. The AUC0-24/MIC ratio for unbound concentrations and for sensitive Staphylococcus and Streptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.
Keyphrases
- adipose tissue
- weight loss
- biofilm formation
- case report
- metabolic syndrome
- minimally invasive
- type diabetes
- obese patients
- gastric bypass
- staphylococcus aureus
- escherichia coli
- coronary artery bypass
- bariatric surgery
- candida albicans
- pseudomonas aeruginosa
- weight gain
- roux en y gastric bypass
- coronary artery disease
- newly diagnosed
- percutaneous coronary intervention